letrozole plus anlotinib

Published: 18 August 2025| Version 1 | DOI: 10.17632/fsn398v4pn.1
Contributors:
Xipeng Wang, Yizhi Wang, Jiarui Li, Yiting Yang, Xin Lu, Hong Xu, Shuhui Zhao, Wenbin Guan

Description

This is the original dataset from the clinical study investigating letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive, platinum-resistant, recurrent epithelial ovarian cancer after failure of second-line therapy.

Files

Categories

Ovarian Cancer

Licence